福安药业12月4日获融资买入2755.94万元，融资余额3.78亿元

Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Fu'an Pharmaceutical, indicating a decrease in revenue and profit for the year 2025 [1][2] - As of December 4, Fu'an Pharmaceutical's stock price increased by 0.87%, with a trading volume of 204 million yuan, and a net financing buy of -792,800 yuan [1] - The company's financing balance reached 378 million yuan, accounting for 6.81% of its market capitalization, which is above the 60th percentile of the past year [1] Group 2 - For the period from January to September 2025, Fu'an Pharmaceutical reported a revenue of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit of 166 million yuan, down 44.87% year-on-year [2] - The number of shareholders for Fu'an Pharmaceutical decreased by 0.49% to 39,100, while the average circulating shares per person increased by 0.49% to 24,753 shares [2] - The company has distributed a total of 688 million yuan in dividends since its A-share listing, with 202 million yuan distributed over the past three years [2]